YMB YM Bio.'b'ser1

    YM BioSciences Announces AeroLEF(TM) Phase IIb Interim Review

     - Benefit observed compared with placebo; Clinical trial to continue as
     planned -

     MISSISSAUGA, ON, Sept. 27 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM,
AIM:YMBA), a company engaged in the acquisition, development and
commercialization of oncology and acute care products, today announced that
its DELEX Therapeutics division has received the results of an interim
analysis on the first 67 patients from its randomized, placebo-controlled
Phase IIb trial (DLXLEF-AP4) of AeroLEF(TM) for the treatment of moderate to
severe acute pain in post-surgical patients. The data indicated that AeroLEF
provided benefit compared to placebo, however the difference between the
treatment arm and placebo arm had not yet achieved the significance level
predefined in the study protocol and therefore the study will continue as
planned to enroll the original target of 99 randomized patients.
     "This preliminary review indicates that we should continue to advance the
AeroLEF phase IIb study to full enrollment," said David Allan, Chairman and
CEO of YM BioSciences. "We look forward to analyzing the full data set at the
completion of the study early next year."
     AeroLEF(TM) is a unique, inhaled-delivery composition of free and
liposome encapsulated fentanyl, for the treatment of moderate to severe acute
pain, including cancer pain. The Phase IIb study consisted of two parts.
Part I was an open label trial of 21 patients to allow investigators to gain
familiarity with administration of the product. Part II is a randomized,
double-blinded, and placebo-controlled trial of 99 patients, and is designed
to evaluate the safety and efficacy of multiple doses of AeroLEF(TM) for
management of pain in post-surgical patients following elective orthopedic
surgeries. The primary endpoint for this study is the Summed Pain Relief plus
Pain Intensity Difference (SPRID) scores during the first four hours after the
start of the initial dose. Secondary endpoints include Time to Effective Pain
Relief, as well as six safety endpoints.
     Preliminary results from the open label portion of the DLXLEF-AP4 trial
will be presented at the American Society of Anesthesiologists Annual Meeting,
McCormick Place, Chicago, IL, on October 17, 2006 at 9:00 a.m. Central.

     About YM BioSciences
     YM BioSciences Inc. is engaged in the acquisition, development and
commercialization of oncology and acute care products. In addition to AeroLEF,
YM BioSciences is developing tesmilifene, nimotuzumab, and Norelin.
     Tesmilifene is a small molecule that targets multi-drug resistant (MDR+)
cancer cells and is being tested in combination with various standard
chemotherapy regimens for the treatment of a number of cancers. The ongoing
'DEC' pivotal trial for tesmilifene in metastatic and recurrent breast cancer
has been the subject of two interim analyses of safety and survival data which
indicated the drug continues to be safe and the trial continues to have the
prospect of meeting its survival endpoint. The third of a number of interim
analyses is anticipated in the coming months and mature data during calendar
2007. In addition to the Phase III DEC trial, which combines tesmilifene with
an anthracycline, a collaborative trial with Sanofi-Aventis is currently
ongoing combining tesmilifene with Taxotere(R) (docetaxel) a taxane drug. A
trial combining tesmilifene with epirubicin, cyclophosphamide, and 5-FU is
anticipated for the treatment of gastric cancer and additional trials are in
planning.
     Nimotuzumab is an anti-EGFR humanized antibody that was recently
partnered in Japan with Daiichi Pharmaceutical Co., Ltd., a subsidiary of
Daiichi Sankyo Company, Limited Nimotuzumab was approved in India in July 2006
for the treatment of head & neck cancer, is currently in a Phase III trial in
Europe in combination with radiation for the treatment of pediatric pontine
glioma and a Phase I/II trial in a specific population of patients with
non-small cell lung cancer in Canada.
     Norelin, an anti-cancer vaccine, stimulates the immune system to develop
antibodies to gonadotropin-releasing hormone (GnRH). In addition, YM
BioSciences owns a portfolio of pre-clinical compounds.

     This press release may contain forward-looking statements, which reflect
the Company's current expectation regarding future events. These
forward-looking statements involve risks and uncertainties that may cause
actual results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include, but are not limited to,
changing market conditions, the successful and timely completion of clinical
studies, the establishment of corporate alliances, the impact of competitive
products and pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to time in the
Company's ongoing quarterly and annual reporting. Certain of the assumptions
made in preparing forward-looking statements include but are not limited to
the following: that the pivotal tesmilifene Phase III trial will be completed
on schedule and yield mature data in calendar 2007; that the DSMB's
recommendations to continue the pivotal trial for tesmilifene based on two
early analyses implies that the trial continues to have the prospect of
meeting its primary endpoint; that nimotuzumab will continue to demonstrate a
competitive safety profile in ongoing and future clinical trials; that YM and
its various partners will complete their respective clinical trials within the
timelines communicated in this release. We undertake no obligation to publicly
update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.

For further information: Thomas Fechtner, The Trout Group LLC, Tel. (212)
477-9007 x31, Fax (212) 460-9028, Email: tfechtner(at)troutgroup.com; James
Smith, The Equicom Group Inc., Tel. (416) 815-0700 x 229, Fax (416) 815-0080,
Email: jsmith(at)equicomgroup.com
(YMBA)



END

YM Bio.'b'ser1 (LSE:YMB)
Historical Stock Chart
From Oct 2024 to Nov 2024

YM Bio.'b'ser1 (LSE:YMB)
Historical Stock Chart
From Nov 2023 to Nov 2024